Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy

JAMA Dermatol. 2016 May 1;152(5):587-9. doi: 10.1001/jamadermatol.2015.5366.

Authors

Sigurdis Haraldsdottir¹, Erin Bertino², Karl Haglund³, Benjamin Kaffenberger⁴, Manisha H Shah²

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.
² Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus.
³ Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus.
⁴ Division of Dermatology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus.

PMID: 26886900
DOI: 10.1001/jamadermatol.2015.5366

No abstract available

Publication types

Case Reports
Clinical Trial, Phase I
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Neoplasms / secondary
Bone Neoplasms / therapy
Carcinoma, Non-Small-Cell Lung / therapy*
Combined Modality Therapy
Diagnosis, Differential
Femoral Neoplasms / therapy
Fracture Fixation, Intramedullary
Fractures, Spontaneous / therapy
Humans
Imidazoles / adverse effects*
Imidazoles / therapeutic use
Indazoles
Lung Neoplasms / therapy*
Male
Middle Aged
Oximes / adverse effects*
Oximes / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
Radiodermatitis / chemically induced*
Radiotherapy, Adjuvant
Sulfonamides / adverse effects*
Sulfonamides / therapeutic use

Substances

Imidazoles
Indazoles
Oximes
Pyrimidines
Sulfonamides
pazopanib
dabrafenib